Alison Templeton
GlaxoSmithKline R&D
Stevenage, ENG, United Kingdom
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Journal: Infectious diseases and therapy
Published: May 25, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Journal: The Journal of infectious diseases
Published: September 13, 2022
Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply.
Journal: The Lancet. Respiratory medicine
Published: September 02, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 17, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Journal: The New England journal of medicine
Published: April 20, 2022
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Respiratory medicine
Published: March 24, 2022
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Journal: International journal of chronic obstructive pulmonary disease
Published: March 10, 2021
Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Journal: Clinical therapeutics
Published: January 23, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026